A biophysics PhD who spent years building radionuclide-production infrastructure, she founded NUCLIDIUM in 2017 to develop copper-based radiopharmaceuticals that are more scalable and affordable for cancer diagnosis and therapy.
Studied at
International Max Planck Research School (PhD, Biophysics)
Before
Programme manager at Radionuclide production infrastructure programs